DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Business Affairs Homepage

Survey finds medical devices not meeting provider expectations A call for higher-quality clinical evidence, flexible contract options and better customer service

Canon elaborates on financial goals with Toshiba Medical in the fold 'Launching into the global health marker ... in one fell swoop'

Former Cleveland Clinic Innovations director pleads guilty to fraud Scheme cost the institution over $2.7 million

NuVasive files lawsuit against former vice chairman Alleges breach of fiduciary duties and violation of contractual obligations

Blue Earth Diagnostics inks Axumin deal with Seibersdorf Laboratories Manufacturing and distribution in certain European countries

2017 AARC Congress: Focus on COPD For four days in Indianapolis, patients took center stage

Amazon may decide to sell prescription drugs online by Thanksgiving Supply chain and regulatory hurdles could make it more trouble than it's worth

Lynn O'Connor Vos Muscular Dystrophy Association appoints CEO

Boston Scientific to acquire Apama Medical Will allow Boston Scientific to enter the single-shot PVI market

Philips inks 5-year maintenance and service agreement with Indonesian hospital group Covers equipment in 21 hospitals

Philips to halt production of external defibrillators in two U.S. facilities

by Lauren Dubinsky , Senior Reporter
Philips North America LLC announced on Wednesday that it will suspend the production of external defibrillators at its operations in Andover, Massachusetts and Bothell, Washington.

These are the terms of a consent decree the company reached with the U.S. government.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory DOTmed Certified



"Following FDA inspections at the Andover and Bothell facilities from 2009 to 2015, FDA investigators made observations regarding Philips' compliance with the Good Manufacturing Practices and medical device reporting requirements of the Food, Drug and Cosmetic Act, with a focus on how Philips addressed issues of its defibrillators," Carla Kriwet, chief business leader of connected care and health informatics at Philips, told HCB News.

The facilities will resume production once FDA inspections confirm that they comply with the Quality System Regulation. Philips has already taken steps to restructure its company-wide Q&R function with new Q&R leadership, reporting lines, training and culture change initiatives.

"Philips takes this matter extremely seriously," said Kriwet. "The company is committed to fulfilling the terms of the Consent Decree, and we have already taken actions since 2015 to address this."

She added that Philips defibrillators currently in use are recommended to remain in use because the company found no reason to believe they pose a risk to patients.

The facilities are still permitted to manufacture and distribute certain automated external defibrillator models, including its HeartStart HS1 AEDs. The company will also continue to service devices in its emergency care and resuscitation portfolio, and provide consumables and relevant accessories.

In 2014, Philips was involved in a similar situation with the FDA that concerned medical scanners at its factories in Cleveland, Ohio. CEO Frans van Houten told Reuters that the current situation is different because Philips had invested in quality control in recent years.

“We have made tremendous progress since 2015 but that didn’t matter,” he said. “This is a consequence of past sins.”

As a result of the decree, Philips expects a loss of about EUR 20 million in the fourth quarter of this year, and about EUR 60 million in 2018. That’s mostly due to the suspension of production, profit disgorgement payments, and incremental costs to prepare for and handle the regulatory inspections.

Back to HCB News
  Pages: 1

Business Affairs Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED